Literature DB >> 20200537

PARP inhibition: PARP1 and beyond.

Michèle Rouleau1, Anand Patel, Michael J Hendzel, Scott H Kaufmann, Guy G Poirier.   

Abstract

Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20200537      PMCID： PMC2910902          DOI： 10.1038/nrc2812

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  136 in total

1.  PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA.

Authors:  Olga Loseva; Ann-Sofie Jemth; Helen E Bryant; Herwig Schüler; Lari Lehtiö; Tobias Karlberg; Thomas Helleday
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

2.  ADP-ribosyl protein lyase. Purification, properties, and identification of the product.

Authors:  J Oka; K Ueda; O Hayaishi; H Komura; K Nakanishi
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

3.  Poly (ADP-Ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain.

Authors:  I Kameshita; Z Matsuda; T Taniguchi; Y Shizuta
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

4.  Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications.

Authors:  Zhihua Tao; Peng Gao; Hung-wen Liu
Journal:  J Am Chem Soc       Date:  2009-10-14       Impact factor: 15.419

5.  Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.

Authors:  Tobias Karlberg; Martin Hammarström; Patrick Schütz; Linda Svensson; Herwig Schüler
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

6.  Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.

Authors:  Philip Jones; Sergio Altamura; Julia Boueres; Federica Ferrigno; Massimiliano Fonsi; Claudia Giomini; Stefania Lamartina; Edith Monteagudo; Jesus M Ontoria; Maria Vittoria Orsale; Maria Cecilia Palumbi; Silvia Pesci; Giuseppe Roscilli; Rita Scarpelli; Carsten Schultz-Fademrecht; Carlo Toniatti; Michael Rowley
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

7.  Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells.

Authors:  Kristine M Frizzell; Matthew J Gamble; Jhoanna G Berrocal; Tong Zhang; Raga Krishnakumar; Yana Cen; Anthony A Sauve; W Lee Kraus
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

8.  Hypermetabolism, hyperphagia, and reduced adiposity in tankyrase-deficient mice.

Authors:  Tsung-Yin J Yeh; Kristina K Beiswenger; Pingping Li; Krista E Bolin; Ray M Lee; Tsu-Shuen Tsao; Anne N Murphy; Andrea L Hevener; Nai-Wen Chi
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

9.  Structural and biophysical studies of human PARP-1 in complex with damaged DNA.

Authors:  Wayne Lilyestrom; Mark J van der Woerd; Nicholas Clark; Karolin Luger
Journal:  J Mol Biol       Date:  2009-12-04       Impact factor: 5.469

10.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137
View more
  573 in total

1.  Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.

Authors:  Wen-Hua Chen; Shan-Shan Song; Ming-Hui Qi; Xia-Juan Huan; Ying-Qing Wang; Hualiang Jiang; Jian Ding; Guo-Bin Ren; Ze-Hong Miao; Jian Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

Review 2.  The role of PARP1 in the DNA damage response and its application in tumor therapy.

Authors:  Zhifeng Wang; Fengli Wang; Tieshan Tang; Caixia Guo
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

3.  Crystal structure of human ADP-ribose transferase ARTD15/PARP16 reveals a novel putative regulatory domain.

Authors:  Tobias Karlberg; Ann-Gerd Thorsell; Åsa Kallas; Herwig Schüler
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

4.  Drug Monographs: Olaratumab and Rucaparib.

Authors:  Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2017-04

Review 5.  How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis.

Authors:  Rana Elkholi; Jerry E Chipuk
Journal:  Bioessays       Date:  2013-10-24       Impact factor: 4.345

6.  The histone variant macroH2A1.1 is recruited to DSBs through a mechanism involving PARP1.

Authors:  Chang Xu; Ye Xu; Ozge Gursoy-Yuzugullu; Brendan D Price
Journal:  FEBS Lett       Date:  2012-09-29       Impact factor: 4.124

7.  AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6.

Authors:  Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

8.  Differential responses of pancreatic β-cells to ROS and RNS.

Authors:  Gordon P Meares; Dominique Fontanilla; Katarzyna A Broniowska; Teresa Andreone; Jack R Lancaster; John A Corbett
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

9.  Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.

Authors:  Wenqi Wu; Hanliang Zhu; Yeping Liang; Zhenzhen Kong; Xiaolu Duan; Shujue Li; Zhijian Zhao; Dong Yang; Guohua Zeng
Journal:  Int Urol Nephrol       Date:  2014-01-17       Impact factor: 2.370

10.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.